Connect with us

Cannabis News

24 Illegal Weed Shops for Every 1 Legal Dispensary

Published

on


ny illegal weed shops

In 2024, after three years of ups and downs, New York’s recreational cannabis market began to gain momentum, notably marked by the opening of approximately 50 licensed dispensaries so far this year.

 

However, these licensed retailers, totaling about 85, find themselves vastly outnumbered by over 2,000 unauthorized head shops. These establishments have drawn complaints for diverting customers, selling to minors, and attracting criminal activity.

 

This swift and audacious incursion has left many frustrated with the government’s slower and more stringent approach to expanding the legal market. It has emerged as the primary challenge confronting the rollout, as authorities grapple with fulfilling the state’s pledge to provide a $5 billion market to a range of small businesses and individuals adversely affected by past anti-marijuana policies.

 

“There needs to be swift action on this,” remarked James Stephenson, co-founder and CEO of oHHo, a wellness brand reliant on dispensaries for distributing its cannabis-infused chocolates, gummies, and seltzers. “There can’t be one group adhering to the rules while others operate outside of them.”

 

Sure, here are some suggested titles for the subheading sections:

 

Challenges in Dispensary Rollout

 

As illicit shops proliferated, the opening of legal dispensaries hit a snag, with months-long delays due to lawsuits, the intricate rule-making process, and the state’s failure to fulfil its commitment to fund the leasing and refurbishing of the initial 150 licensed dispensaries. Currently, only 10 stores are operational with state assistance, while another 375 dispensaries, licensed for nine months or longer, remain closed.

 

Governor Kathy Hochul, expressing growing dissatisfaction, recently initiated a review of the Office of Cannabis Management, the entity overseeing the rollout. Additionally, she proposed legislation to empower local authorities to crack down on unlicensed shops and landlords complicit in their operations. Furthermore, she introduced a bill to reduce taxes that inflate the prices of legal cannabis products, a move widely supported in the State Legislature.

 

The review commenced shortly after Damian Fagon, the cannabis agency’s chief social equity officer, was placed on administrative leave pending a misconduct investigation. This action followed allegations by Jenny Argie, the founder of a licensed cannabis business, accusing Fagon of retaliation after she recorded a conversation with him, subsequently cited in an article criticizing the agency.

 

Argie subsequently filed a lawsuit against the state, joining a slew of legal challenges against the agency. These include allegations that the state’s social equity policies unfairly favor women and minorities over white men, and efforts to halt the use of lotteries in determining the order of new application consideration. Other lawsuits contest decisions regarding dispensary locations and oppose the use of taxpayer funds to support them.

 

Chris Alexander, the executive director of the state cannabis agency, has stood by his agency’s deliberate and systematic approach to licensing businesses owned by a diverse array of individuals, which regulators believe can thrive in a notoriously challenging industry. He highlights the shortcomings experienced by states that rushed their processes. Additionally, officials express frustration that the criticisms of the rollout have overshadowed the accomplishments made in the two years since the agency’s inception.

 

Licensed Dispensaries vs. Illicit Market

 

New York currently boasts more licensed recreational dispensaries than any other state on the East Coast, second only to Massachusetts. These establishments are owned by individuals with diverse backgrounds, including those with criminal records, veterans, women, nonprofits, and individuals of Black, Latino, and Asian descent. These dispensaries have significantly contributed to job creation in a retail sector grappling with the aftermath of the pandemic, alleviated the state’s surplus of unsold cannabis, and generated substantial tax revenue, amounting to millions of dollars. Many of these businesses are profitable and expanding, with numerous newcomers on the brink of breaking even.

 

Despite these achievements, licensed dispensaries face challenges in attracting consumers away from illicit shops, as many consumers are unaware or indifferent to the distinction between licensed and unlicensed establishments. In the first full year of legal sales, state-licensed dispensaries in New York generated approximately $150 million, considerably less than the $673 million generated by dispensaries in New Jersey, where recreational sales commenced eight months prior.

 

Unlike New Jersey and Massachusetts, which permitted medical dispensaries to transition into recreational sales, New York initially prioritized retail licenses for individuals with criminal records and only recently allowed medical dispensaries to serve the public. Critics, including some supporters, argue that this decision exposed the program to legal challenges, leading to delays in the rollout while the illicit market flourished.

 

With limited avenues to sell their products, cannabis farmers in New York are facing financial hardships amidst an expanding market.

 

During a recent Cannabis Control Board meeting in Brooklyn, the first since the governor ordered a review, several applicants and licensees expressed their frustrations. Some defended the regulators, acknowledging the daunting task of developing the industry with insufficient resources.

 

Reform Efforts and Support Initiatives

 

The board passed a resolution that exempts new licensing fees for those wishing to continue cultivation for the state or establish craft businesses.

 

Damien Cornwell, president of the Cannabis Association of New York, which advocated for the exemption, argued that the fees, reaching as high as $40,000, pose a significant barrier for farmers. Many have depleted their funds on taxes while awaiting payment from retailers for product orders.

 

“They’re cash-strapped,” remarked Mr. Cornwell, who also operates a dispensary named Just Breathe in Binghamton. “Their liquidity is insufficient for this endeavor.”

 

Despite numerous raids by local and state authorities on illicit stores, hefty fines and pressure on landlords to evict unlicensed businesses, these retailers persist undeterred. They often reopen shortly after raids and contest fines through lengthy administrative hearings.

 

In addition to Governor Hochul’s proposals for enforcement and tax reform, state legislators are considering measures to provide financial aid to struggling farmers and safeguard a special licensing program for individuals with prior marijuana-related convictions from legal challenges. New York City prosecutors are also seeking expanded authority to evict shops involved in the marketing and sale of cannabis.

 

“I want an effective system,” stated Jeremy Cooney, a state senator from Rochester and chairman of the cannabis subcommittee.

 

Pilar DeJesus, a housing activist and advocate for cannabis legalization, emphasized that the state should offer more assistance to individuals adversely affected by anti-cannabis policies in establishing legal businesses.

 

The demand for such support has surged. Last autumn, the Office of Cannabis Management received 7,000 license applications, with approximately 4,800 applicants qualifying for mandated loans and grants. These funds are designed to aid businesses owned by low-income individuals with previous arrests, as well as by women, minorities, veterans, and struggling farmers.

 

While the Office of Cannabis Management offers some reimbursement to organizations aiding applicants, Ms DeJesus argued for increased funding directed towards grassroots organizations already assisting in developing the necessary skills for operating businesses in the cannabis industry.

 

“We’re talking about a range of skill sets that the community lacks due to barriers created by the war on drugs,” she emphasized.

 

Bottom Line

 

New York’s cannabis industry faces significant hurdles as it navigates the challenges of legalization. Despite progress in licensing dispensaries, the proliferation of illicit shops remains a pressing concern, highlighting the need for swift regulatory action. Governor Kathy Hochul’s proposed reforms and support initiatives signal a commitment to addressing these issues, but substantial work lies ahead to ensure the industry’s equitable and sustainable growth. Collaboration between regulators, legislators, advocates, and industry stakeholders will be crucial in overcoming obstacles and realizing the full potential of New York’s cannabis market.

 

NEW YORK TRIES TO SHUT DOWN ILLEGAL WEED SHOPS, READ ON…

NY TRIES TO SHUT DOWN ILLEGAL MARIJUANA SHOPS

NY TRIES TO SHUT DOWN ILLEGAL CANNABIS SHOPS, GOOD LUCK SAYS CA!



Source link

Cannabis News

Do Psychedelic Mushrooms Have an Entourage Effect Similar to Cannabis?

Published

on

By


psychedelc entrourage effect

Understanding How The Entourage Effect Works In Psychedelic Mushrooms

Learn fascinating ways about how magic mushrooms work!

 

Most of us are already familiar with the entourage effect in marijuana. In essence, the entourage effect means that the therapeutic compounds in cannabis work more efficiently with one another, synergistically, to provide health benefits that are more powerful compared to when we take compounds on its own. While there are cannabis products that isolate THC and CBD, the science tells us that taking flower or full-spectrum form, where other cannabinoids and terpenes are present, are much more effective than one compound on its own.

 

The concept of the entourage effect was discovered in 1999 by none other than Raphael Mechoulam, the famous godfather of THC. Up until recently, most of what we know about the entourage effect has been limited to cannabis plants.


Now, there’s new data suggesting that the same can be observed when medicating with psychedelic mushrooms.

 

After all, psilocybin mushrooms – just like marijuana – also contain a complex array of other compounds, not just the star compound they are known for. While we do have some knowledge of how psilocybin works in the body thanks to clinical tests, keep in mind they do make use of synthesized psilocybin for research most of the time.

 

According to a recent study, psilocybin extracts may have more powerful health benefits for treating depression, OCD, anxiety, and PTSD to name a few because of the other psychoactive as well as non-psychoactive compounds in the mushroom.  “My colleagues and I are very interested in the potential of psychedelics to treat serious, treatment resistant psychiatric disorders such as depression, PTSD, OCD and even schizophrenia,” explains Bernard Lerer, study author and a psychiatry professor and director at the Hadassah BrainLabs Center for Psychedelic Research at Hebrew University.

 

“There are many anecdotal and clinical reports which suggest that extract of psilocybin-containing mushrooms may have unique effects that are qualitatively and quantitatively different from chemical psilocybin, and also some preclinical studies. This observation has important clinical implications and we wanted to test it empirically in a laboratory study,” they said. So for the study, the researchers compared naturally-derived mushroom extracts to chemically made psilocybin, with the intention of discovering whether the other compounds within the extract can provide benefits that are not found when consuming isolated psilocybin.

 

The researchers utilized male adult mice for the trials; they were divided into groups: some were given the naturally occurring mushroom extracts, while the others were given the synthetic psilocybin. Meanwhile, others were given a control solution made of saline. Additionally, the researchers analyzed the heat twitch response (HTR) assay, which is a reputable method for analyzing the impacts of psychedelics on mice. Furthermore, the researchers analyzed the mice in a molecular and biochemical level to understand any synaptic protein expressions within the brain, which are features of neuroplasticity.

 

The results were astonishing: they found that the brains of the mice who were given the naturally occurring mushroom extracts showed more significant neuroplasticity markers through the presence of synaptic proteins, specifically GAP43, SV2A, PSD95, and synaptophysin. Since these proteins are required for development, synaptic growth, and neuroplasticity, these findings suggest that naturally occurring mushroom extracts may indeed have a more powerful impact compared to psilocybin isolate.

 

“Our findings need to be confirmed in human studies but they do suggest that there may be therapeutic advantages to psilocybin-containing mushroom extract over chemically synthesized psilocybin, when both are administered at the same psilocybin dose,” explains Lerer to Psypost.

 

So Much We Need To Uncover In The World Of Mushrooms

 

When magic mushrooms are cultivated and extracted naturally, the sub metabolites of the plant remain intact, unlike the isolated versions that are synthetically produced in a laboratory since it only contains psilocybin.  There are several examples, such as the Baeocystin tryptamine, which can induce mild hallucinogenic effects. Beta-carbolines have also been discovered in psychedelic mushrooms, which can effectively help metabolize psilocin in the human body, causing a more intensive psychedelic experience.


But Why Is It Harder To Study Mushrooms Compared To Marijuana?

 

While the entourage effect of cannabis is already widely studied and better understood, the opposite is true when it comes to psychedelic mushrooms. There’s still so much we need to understand and study better; rodent studies are a start but translating them to humans is a whole other ball game. In addition, other experts have already acknowledged the challenges of identifying such impacts of the entourage effect.

 

For instance, Alan Rockefeller, a renowned mycologist who specializes in DNA sequencing as well as photography of fungi, tells Psychedelic Health: “No one really knows whether the entourage effect occurs with mushrooms.”

He goes on to elaborate the difficulties associated with studying mushrooms: “It is difficult to study because the same batch of mushrooms will have different effects in different people, and the same person on different days,” Rockefeller said. Also, it’s difficult to understand which compounds are active in a plant or mushroom, and how large the impact is for the active compounds. Researchers also need to understand the concentrations of each compound, and how different growing environments or processing can impact it.

 

“There are a dozen different tryptamines that can occur in mushrooms, plus a few beta-carbolines and hundreds of other molecules – so there is probably more than just psilocybin having an effect,” Rockefeller said. “Studying one compound at a time is hard enough, studying mixtures of hundreds of compounds is much more difficult. Without pure compounds, it is difficult to get repeatable results,” Rockefeller said. “It is possible that the therapeutic potential is different depending on the different compounds in the mushrooms. It’s also possible that psilocybin is the only thing that matters, and the other compounds are mostly inactive,” he said.


Conclusion

 

There’s so much yet that we need to know about how psychedelic mushrooms work. However, the possibilities that can be brought about by harnessing the power of the entourage effect in magic mushrooms is incredibly exciting. There is so much potential in this field that we can only truly uncover with more studies.

 

ARE PSYCHEDELICS CANNABIS 2.0? READ ON…

PSYCHEDELICS TRADE SHOW

ARE PSYCHDELICS JUST CANNABIS 2.0? BENZINGA SHOW RECAP!



Source link

Continue Reading

Cannabis News

The Dangers and Effects of THC Vape in UK

Published

on

By


cbd oil vape king UK

People in the UK increasingly realize that CBD vaping is quite safe. Even NHS recommends CBD vaping as one of the relatively safer ways to quit smoking. Vaping is not without any harm, but it is much safer than tobacco smoking. Even more, CBD vaping is associated with some good health effects. However, now people are realizing that THC vape pens could be an even more potent way of enjoying CBD’s health benefits.

What is THC Vape?

If readers noticed that in the introduction of this text, we talked about CBD, there is a reason for that. THC vaping is different from CBD vaping, but not entirely. It has much in common with it.

The hemp plant is rich in many cannabinoids. Two major cannabinoids are THC (Tetrahydrocannabinol) and CBD (Cannabidiol). It also has many minor cannabinoids in smaller amounts, like CBG, CBC, CBN, THCV and CBDV. CBD vape pens generally have all these compounds except THC.

However, THC vape differ in the way that they also contain small amounts of THC along with CBD, minor cannabinoids, and other beneficial organic compounds like terpenes for added flavour and enhanced vaping experience.

So, why do some of the vape pens have added THC in small amounts? After all, THC is known to be addictive and has mind-altering properties. Well, the explanation is simple: the secret is in the dosage. In smaller and legally permitted dosages, THC does not cause a high; it is safe and can have many health benefits.

When small amounts of THC are added to CBD, minor cannabinoids, and terpenes, it results in much more powerful health benefits. That is why some of the CBD-based clinically approved drugs also contain THC.

THC vape pens may also have some distinct benefits not experienced with CBD vape pens. This is due to “the entourage effect.” The entourage effect is a bit different from synergy. Synergy is like two-plus-two equal to five, meaning that using some compounds together results in a more potent effect, yet safety is not compromised. However, the entourage effect means combining two compounds may result in some unique health benefits not seen when those compounds are used in isolation. So, the entourage effect is more powerful and unique than synergy.

Therefore, using THC vape pens means some unique health benefits, although these vape pens contain THC in small amounts.

THC Vape: The Dangers

It is no secret that THC is the main compound responsible for all side effects of the cannabis plant. This substance is addictive and, at higher dosages, causes euphoria, has potent mind-altering properties, and may cause hallucinations.

However, there is one important thing to understand. All these effects of THC are seen at much higher dosages than those in legally produced THC vape pens.

Legally produced/sold vape pens in the UK, like those by CBDoilking, do not contain THC more than 0.2%. This is significantly lower than cannabis indica or marijuana, which may contain 25% or even more THC. So, there is no comparison between legal THC vape pens and marijuana. At these small dosages, THC does not cause euphoria or other side effects and has no addictive properties. It only has mild stress-relief properties at these dosages.

Secondly, THC vape pens sold by CBDoilking follow other important UK guidelines and legal requirements, which means that THC vape pens cannot contain more than 1 mg of THC. Hence, it is not just about low concentration but also about low amounts, thus ensuring its safety.

Safe and Potent THC vape pens

THC vape pens are for health-conscious individuals who would like to vape on a regular basis. It is safe and may have beneficial effects like reduced anxiety, improved mood, and enhanced sleep, and it may also help reduce pain sensation.

THC vape pen is even better than your regular CBD vape pen for quitting smoking. This is because it is better at reducing tobacco cravings.

CBDoilking sells one of the strongest THC vape pens in the market (75-80% CBD plus CBG along with THC in permitted amounts), and yet all pens sold on the platform follow strict legal guidelines. All the products undergo third-party testing and are proven to contain THC, CBD, and other minor cannabinoids within legally permitted and safe limits.

Another good thing about CBDoilking is that these excellent THC vape pens come in many flavours. These flavours are not due to some artificial substances but rather due to their content of terpenes. Terpenes are plant-based aromatic compounds with antioxidant and anti-inflammatory properties.

CBDoilking offers vapes that are based on science, combining different natural compounds in the right ratio. This is both about safety and potency. So, these products are really good for those looking for something better, potent, and yet safe.

The Bottom Line

CBD vape pens have been around for some time, and their safety is well-established. They are an excellent way to quit smoking and also enjoy CBD’s health effects. However, some people are looking for something more potent. THC vape pens are good for such individuals. These contain all beneficial compounds present in the cannabis plant but in the right proportions.

THC vape pen is a new way to enjoy vaping. It is unlikely to cause any side effects as these products are made for regular use. Of course, one should not overdose on THC or CBD. It is important not to have more than a few puffs a day. Rare side effects like nausea or stomach issues might occur but are transient and short-lived. Such issues are rarely the cause of concern, except in a very small number of cases.

Thus, if you are looking for something better to reduce stress and overcome pain and anxiety, then a THC vape pen may be the right choice. Choosing something strong like the one offered by CBDoilking may be a good idea. Despite being strong, these vape pens contain THC only in legally permitted amounts and in concentrations proven to be safe and not cause euphoria.

To sum up, if you are already an experienced CBD vaper, it may be a good idea to give THC vaping a try.

 

CBD VAPE OIL SAFETY, READ ON…

BENEFITS OF CBD VAPE OIL

3 BIG BENEFITS OF CBD VAPE OIL CARTS, WHY DO THEY WORK?



Source link

Continue Reading

Cannabis News

How to Buy or Sell a Cannabis Business: The Webinar Replay

Published

on

By


For anyone who wasn’t able to join us on April 17th, the video replay of our webinar titled “How to Buy or Sell a Cannabis Business” is now available on our website. You can view it here.

The description of this webinar is also included directly below. Enjoy!

____

On Wednesday, April 17, 2024 at 12:00 pacific time, Harris Sliwoski managing partner Vince Sliwoski (Portland), Harris Sliwoski partner Griffen Thorne (Los Angeles), and Andy Shelley of CannXperts will present a free webinar entitled “How to Buy or Sell a Cannabis Business.”

Drawing on their extensive experience from representing businesses and entrepreneurs across numerous M&A transactions, including crucial state license transfers throughout the United States, our panelists will share insights and practical wisdom from their firsthand experiences in the legal cannabis industry.

  • Crafting and understanding Letters of Intent
  • Conducting thorough Due Diligence
  • Drafting and Negotiating purchase agreements and ancillary documents
  • Navigating State-Specific Regulatory Concerns
  • Managing Escrow Challenges
  • Optimizing Financial Arrangements: Purchase Prices, Holdbacks, Earnouts
  • Tackling Post-Closing Considerations

As always, we’ll also take Q&A, so please feel free to either submit questions when registering or you will be able to ask comments in chat during the webinar.



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media